Bladder cancer patient and provider perspectives on smoking cessation Journal Article


Authors: Mossanen, M.; Smith, A. B.; Onochie, N.; Matulewicz, R.; Bjurlin, M. A.; Kibel, A. S.; Abbas, M.; Shore, N.; Chisolm, S.; Bangs, R.; Cooper, Z.; Gore, J. L.
Article Title: Bladder cancer patient and provider perspectives on smoking cessation
Abstract: Background: Smoking is the most common risk factor for bladder cancer and is associated with adverse clinical and cancer-related outcomes. Increasing understanding of the patient and provider perspectives on smoking cessation may provide insight into improving smoking cessation rates among bladder cancer survivors. We sought to inform strategies for providers promoting cessation efforts and help patients quit smoking. Methods: Using a modified Delphi process with multidisciplinary input from bladder cancer providers, researchers, and a patient advocate, 2 surveys were created for bladder cancer patients and providers. Surveys included multiple-choice questions and free answers. The survey was administered electronically and queried participants’ perspectives on barriers and facilitators associated with smoking cessation. Survey responses were anonymous, and participants were provided with a $20 Amazon gift card for participating. Patients were approached through the previously established Bladder Cancer Advocacy Network (BCAN) Patient Survey Network, an online bladder cancer patient and caregiver community. Providers were recruited from the Society of Urologic Oncology (SUO) and the Large Urology Group Practice Association (LUGPA). Results: From May to June 2021, 308 patients and 103 providers completed their respective surveys. Among patients who quit smoking, most (64%) preferred no pharmacologic intervention (“cold turkey”) followed by nicotine replacement therapy (28%). Repeated efforts at cessation commonly occurred, and 67% reported making more than one attempt at quitting prior to eventual smoking cessation. Approximately 1 in 10 patients were unaware of the association between bladder cancer and smoking. Among providers, 75% felt that barriers to provide cessation include a lack of clinical time, adequate training, and reimbursement concerns. However, 79% of providers endorsed a willingness to receive continuing education on smoking cessation. Conclusions: Bladder cancer patients utilize a variety of cessation strategies with “cold turkey” being the most used method, and many patients make multiple attempts at smoking cessation. Providers confront multiple barriers to conducting smoking cessation, including inadequate time and training in cessation methods; however, most would be willing to receive additional education. These results inform future interventions tailored to bladder cancer clinicians to better support provider efforts to provide smoking cessation counseling. © 2023 Elsevier Inc.
Keywords: adult; cancer chemotherapy; aged; major clinical study; gemcitabine; cancer patient; cancer radiotherapy; cancer staging; bcg vaccine; cancer immunotherapy; patient education; smoking cessation; smoking; bladder cancer; bladder tumor; risk factor; urinary bladder neoplasms; groups by age; cancer survivor; docetaxel; reimbursement; patient participation; cystectomy; urinary bladder; health care personnel; delphi study; continuing education; patient counseling; race; bladder; survey; nicotine replacement therapy; nicotine gum; procedures; patient advocacy; multiple choice test; patient perspectives; transurethral resection of the bladder; humans; human; male; female; article; multidisciplinary team; current smoker; ex-smoker; tobacco use cessation devices; provider perspectives
Journal Title: Urologic Oncology: Seminars and Original Investigations
Volume: 41
Issue: 11
ISSN: 1078-1439
Publisher: Elsevier Inc.  
Date Published: 2023-11-01
Start Page: 457.e9
End Page: 457.e16
Language: English
DOI: 10.1016/j.urolonc.2023.08.017
PUBMED: 37805339
PROVIDER: scopus
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors